Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Middleton

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Genes & Development|January 19, 2017
Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanomaPaola Falletta, Luis Sanchez-Del-Campo, Jagat Chauhan, et al.
British Journal of Cancer|November 6, 2022
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancerGiuseppe Curigliano, Geoffrey I Shapiro, Rebecca S Kristeleit, et al.
Molecular Cell|June 13, 2020
Tuning Transcription Factor Availability through Acetylation-Mediated Genomic RedistributionPakavarin Louphrasitthiphol, Robert Siddaway, Alessia Loffreda, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2019
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019Claus Garbe, Teresa Amaral, Ketty Peris, et al.
European Journal of Cancer (Oxford, England : 1990)|May 17, 2019
Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)Celeste Lebbe, Claus Garbe, Alexander J Stratigos, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2020
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019Claus Garbe, Teresa Amaral, Ketty Peris, et al.
Cancer Chemotherapy and Pharmacology|October 22, 2013
A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumoursLaura Horsley, Jeff Cummings, Mark Middleton, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2023
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAF<sup>V600</sup> mutant advanced melanoma (INTERIM)Alimu Dayimu, Avinash Gupta, Rubeta N Matin, et al.
Journal for Immunotherapy of Cancer|April 19, 2024
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic diseaseJason J Luke, Diwakar Davar, Robert H Andtbacka, et al.
The Journal of Animal Ecology|October 23, 2025
An integrative, peer-reviewed and open-source cooperative-breeding database (Co-BreeD)Yitzchak Ben Mocha, Maike Woith, Sophie Scemama de Gialluly, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Genes & Development|January 19, 2017
Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanomaPaola Falletta, Luis Sanchez-Del-Campo, Jagat Chauhan, et al.
British Journal of Cancer|November 6, 2022
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancerGiuseppe Curigliano, Geoffrey I Shapiro, Rebecca S Kristeleit, et al.
Molecular Cell|June 13, 2020
Tuning Transcription Factor Availability through Acetylation-Mediated Genomic RedistributionPakavarin Louphrasitthiphol, Robert Siddaway, Alessia Loffreda, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2019
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019Claus Garbe, Teresa Amaral, Ketty Peris, et al.
European Journal of Cancer (Oxford, England : 1990)|May 17, 2019
Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)Celeste Lebbe, Claus Garbe, Alexander J Stratigos, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2020
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019Claus Garbe, Teresa Amaral, Ketty Peris, et al.
Cancer Chemotherapy and Pharmacology|October 22, 2013
A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumoursLaura Horsley, Jeff Cummings, Mark Middleton, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2023
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAF<sup>V600</sup> mutant advanced melanoma (INTERIM)Alimu Dayimu, Avinash Gupta, Rubeta N Matin, et al.
Journal for Immunotherapy of Cancer|April 19, 2024
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic diseaseJason J Luke, Diwakar Davar, Robert H Andtbacka, et al.
The Journal of Animal Ecology|October 23, 2025
An integrative, peer-reviewed and open-source cooperative-breeding database (Co-BreeD)Yitzchak Ben Mocha, Maike Woith, Sophie Scemama de Gialluly, et al.
Pageof 6